Telix Pharmaceuticals Ltd 6-K, filed Feb 18, 2026
Telix Pharmaceuticals Ltd (TLX)
6-K
2026-02-18
For: 2026-02-17
View Original
Added on
April 07, 2026
About this 6-K
Telix Pharmaceuticals Ltd filed this 6-K on February 18, 2026.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the month of February, 2026
Commission File Number: 001-42128
Telix Pharmaceuticals Limited
(Translation of registrant’s name into English)
55 Flemington Road
North Melbourne, Victoria 3051, Australia
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
1
INFORMATION CONTAINED IN THIS FORM 6-K REPORT
On February 18, 2026 (Melbourne, Australia), Telix Pharmaceuticals Limited filed an announcement with the Australian Securities Exchange titled “Telix Submits European Marketing Authorization Application for TLX101-Px for Brain Cancer Imaging,” which is attached to this Form 6-K as Exhibit 99.1.
|
Press Release – February 18, 2026
|
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
Telix Pharmaceuticals Limited
|
|
|
|
|
|
|
Date: February 18, 2026
|
By:
|
/s/ Genevieve Ryan
|
|
|
|
Name: Genevieve Ryan
|
|
|
|
Title: Company Secretary
|
